Viewing data from:

DIAZOXIDE

ANDA

DIAZOXIDE | A071519 | ABRAXIS PHARMACEUTICAL PRODUCTS

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Diazoxide (2023)

Total Spending

$2.6M

Total Claims

2,276

Beneficiaries

525

Avg Cost/Unit

$8.45

Spending Trend

$994K(2020)→$2.3M(2021)→$2.2M(2022)→$2.6M(2023)

YoY Change:-3.7%

5yr CAGR:-2.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain6 active DMFs1 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

LUNDBECK PHARMACEUTICALS ITALY SPADIAZOXIDE

DMF 70311987

NOVITIUM PHARMA LLCDIAZOXIDE USP

DMF 312492017

BIOPHORE INDIA PHARMACEUTICALS PVT LTDDIAZOXIDE

DMF 323352017

GUANG'AN KINGDAY PHARMA AND CHEM CO LTDDIAZOXIDE USP

DMF 327712018

MSN LABORATORIES PRIVATE LTDDIAZOXIDE USP

DMF 353512020

SUZHOU YIFAN PHARMACEUTICAL CO LTDDIAZOXIDE

DMF 428902025

TRANSO PHARM PRODUKTIONS GMBHInactiveDIAZOXIDE

DMF 168192003

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 15MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Aug 26, 1987

No patent or exclusivity listings for this strength.